Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.5 SEK | -2.40% | +45.51% | -15.14% |
Sales 2023 | 35.2M 3.29M | Sales 2024 * | 105M 9.82M | Capitalization | 615M 57.46M |
---|---|---|---|---|---|
Net income 2023 | -249M -23.27M | Net income 2024 * | -223M -20.84M | EV / Sales 2023 | 18.7 x |
Net cash position 2023 | 66.92M 6.25M | Net cash position 2024 * | 214M 19.98M | EV / Sales 2024 * | 3.82 x |
P/E ratio 2023 |
-2.78
x | P/E ratio 2024 * |
-3.61
x | Employees | 57 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 89.19% |
Latest transcript on Oncopeptides AB
1 day | -2.40% | ||
1 week | +51.30% | ||
Current month | +34.69% | ||
1 month | +26.21% | ||
3 months | -14.83% | ||
6 months | -23.98% | ||
Current year | -15.14% |
Managers | Title | Age | Since |
---|---|---|---|
Sofia Heigis
CEO | Chief Executive Officer | 44 | 20-07-31 |
Director of Finance/CFO | 50 | Nov. 12 | |
Klaas Bakker
CTO | Chief Tech/Sci/R&D Officer | 42 | 19-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Per Wold-Olsen
CHM | Chairman | 76 | 18-05-16 |
Director/Board Member | 63 | 11-12-31 | |
Director/Board Member | 61 | 17-01-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 6.5 | -2.40% | 617,154 |
24-03-27 | 6.66 | +26.18% | 1,940,400 |
24-03-26 | 5.278 | +3.78% | 344,943 |
24-03-25 | 5.086 | -5.81% | 589,946 |
24-03-22 | 5.4 | +20.89% | 2,138,884 |
Delayed Quote Nasdaq Stockholm, March 28, 2024 at 07:59 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.14% | 59.32M | |
+2.73% | 108B | |
+9.59% | 104B | |
+6.58% | 23.66B | |
-12.59% | 22.1B | |
-3.29% | 19.71B | |
-35.36% | 18.2B | |
-13.29% | 16.19B | |
+4.68% | 13.72B | |
+34.25% | 12.22B |